Cholesteryl butyrate in solid lipid nanospheres as an alternative approach for butyric acid delivery

Anticancer Research

Volumn 19, Issue 5 B, 1999, Pages 3921-3925

  Pellizzaro, Cinzia ^a   Coradini, Danila ^a   Morel, Silvia ^b   Ugazio, Elena ^c   Gasco, Maria Rosa ^c   Daidone, Maria Grazia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Butyrate; Cholesteryl butyrate; Drug delivery; Lung tumor cells; Solid lipid nanospheres

Indexed keywords

BUTYRIC ACID; CHOLESTEROL ESTER; COUMARIN; NANOPARTICLE; PRODRUG;

ARTICLE; CANCER CELL CULTURE; CELL LEVEL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL;

EID: 0032763014     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J and Powell J: Cancer incidence in five continents. IARC Sci Publ No. 120, Lyon, 1992.
2. Bains M: Surgical treatment of lung cancer. Chest 100: 826-837, 1991.
3. Fukuyama Y, Mitsudomi T, Sugio K, Ishida T, Akazawa K and Sugimachi K: K-ras and p53 mutations are independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer 75: 1125-1130, 1997.
4. Salgia R and Skarin AT: Molecular abnormalities in lung cancer. J Clin Oncol 16: 1207-1217, 1998.
5. Rak J, Filmis J, Finkenzeller G, Grugel S, Marme D and Kerbel RS: Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 14: 263-277, 1995.
6. Landon SP, Hawkes MM, Hay FG, Lawrie SS, Schol DJ, Hilgers J and Leonard RCF: Effect of sodium butyrate and other differentiation inducers on poorly differentiated human ovarian adenocarcinoma cell lines. Cancer Res 48: 6161-6165, 1988.
7. Hodin RA, Meng S, Archer S and Tang R: Cellular growth state differentially regulates enterocyte gene expression in butyrate-treated HT29 cell. Cell Growth Diff 7: 647-653, 1996.
8. Coradini D, Biffi A, Costa A, Pellizzaro C, Pirronello E and Di Fronzo G: Effect of sodium butyrate on human breast cancer cell lines. Cell Prolif 30: 149-159, 1997.
9. Yamamoto H, Fujimoto J, Okamoto E, Furuyama J, Tamaoki T and Hashimoto-Tamaoki T: Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro end in vivo. Int J Cancer 76: 897-902, 1998.
10. Krupitza G, Harant H, Dittrich E, Szekeres T, Huber H and Sittrich C: Sodium butyrate inhibits c-myc splicing and interferes with signal transduction in ovarian carcinoma cells. Carcinogenesis 16: 1199-1205, 1995.
11. Velasquez OC, Zhou D, Seto RW, Jabbar A, Choi J, Lederer HM and Rombeau JL: In vivo crypt surface hyperproliferation is decreased by butyrate and increased by deoxycholate in normal rat colon: associated in vivo effects on c-fos and c-jun expression. J Parenteral Enteral Nutr 20: 243-250, 1996.
12. Mandal M and Kumar R: Bcl-2 expression regulates sodium butyrate-induced apoptosis in human breast cancer cells. Cell Growth Diff 7: 311-318, 1996.
13. Janson W, Brandner G and Siegel J: Butyrate modulates DNA-damage-induced p53 response by induction of p53-independent differentiation and apoptosis. Oncogene 15: 1395-1406, 1997.
14. Miller AA, Kurschel E, Osieka R and Schmidt C: Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 23: 1283-1287, 1987.
15. Morel S, Gasco MR and Cavalli R: Incorporation in lipospheres of (D-TRP-6)LHRH. Int J Pharm 105: R1-R4, 1994.
16. Gasco MR, Morel S and Carpignano R: Optimization of the incorporation of deoxycorticosterone. Eur J Pharm Biopharm 38: 7-10, 1992.
17. Cavalli R, Caputo O, Carlotti ME, Trotta M, Scarnacchia C and Gasco MR: Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm 148: 47-54, 1997.
18. Cavalli R, Morel S, Gasco MR, Chetoni P, Saettone MF and Mariotti-Bianchi L: In vitro/in vivo evaluation of colloidal lipospheres containing pilocarpine as ion pair. 1st World Meeting (APGI/APV), Budapest, Hungary, 1995.
19. Cavalli R, Bargoni A, Caputo O, Fundaro A, Zara GP and Gasco MR. Solid lipid nanoparticles incorporating doxorubicine: preliminary pharmacokinetics results. Proc. 2nd World Meeting APGI/APV, Paris, 25-28 May 1998.
20. Bargoni A, Cavalli R, Caputo O, Fundaro A, Gasco MR and Zara GP: Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res 15: 745-750, 1998.
21. Duncan IW, Culbreth PH and Burts CA: J Chromatography 162: 281-292, 1979.
22. Carney DN, Gazdar AF, Bepler F, Guccion JG, Marangos PJ, Moody TW, Zweig MH and Minna LD: Establishment and identification of small cell lung cancer lines having classic and variant features. Cancer Res 45: 2913-2923, 1985.